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Glucocorticoid administration to pregnant women
at the appropriate time during pregnancy acceler-
ates maturation of the fetal lung [8]. Use of such
therapy is indicated in all cases in which a prema-
ture delivery is expected or medical reasons re-
quire it. This is generally necessary up to the end
of the 34th week of pregnancy or in cases of
detected immaturity of the lung [10].
The main indications are:
— premature contractions,
— hemorrhage during pregnancy,
— conditions of fetal distress,
— maternal diseases.
Predominant among the four main indications is
the respiratory distress symdrome prophylaxis in
cases of imminent premature birth. Cases of a
imminent or expected premature birth frequently
requires tocolysis, which involves particular prob-
lems in connection with the glucocorticoid treat-
ment. Here it must be clarified whether the combi-
nation of tocolysis and glucocorticoid therapy
does not lead to an unjustifiable endangering of
the mother.
Hemorrhage during pregnancy as the indicator
of an atypical placenta insertion must always be
interpreted as a potential premature or early deliv-
ery risk. By conditions of fetal distress, we mean
the few cases with fetal distress which still permit
temporal prolongation of the delivery until the
corticoid effect has been attained. There also fre-
quently include multiple pregnancies, where deliv-
ery is usually before them.
Increasingly rare are the cases that require prema-
ture delivery for early extrauterine therapy in the
fetus, as, for instance, rhesus incompatibility or
surgically correctable fetal anomalies. Maternal
indications for premature delivery are extremely
rare in Europe and also in the United States.
We regard the following as absolute or relative
contraindications:
— severe forms of preeclampsia,
— diabetes mellitus,
— premature rupture of membranes,
— maternal and/or intrauterine infections.
In our opinion, the combination of tocolysis and
glucocorticoid therapy demands intensive medical
surveillance, above all, strict balancing of the
water equilibrium and electrolyte metabolism.
Tocolysis may cause retardation of surfactant syn-
thesis [5]. The combination with glucocorticoids
appears useful.
WOLFF [15] was able to clearly demonstrate by
cardiac catheter examination that the pulmonary
vascular resistance cannot be considered as causal
for intrapulmonary pressure increase and tend-
ency towards edema formation, which is a possible
risk under the combination therapy with tocolysis
and glucocorticoids. LIGGINS [9] already empha-
sized in 1976 that eclampsia and preeclampsia
must be regarded as a contraindication for steroid
therapy. LAMONT and co-workers [7], on the other
hand, saw advantages for the fetus in a glucocorti-
coid therapy even in the presence of severe hyper-
tension. In any case, careful consideration is nec-
essary in carrying out such therapy in this group
of patients. If such therapy is used, strict intensive
medical precautions must be taken. Otherwise, the
therapy is rejected because of the high intrauterine
mortality rate of the fetuses in the course of the
basic disease and, in connection with a combina-
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tion therapy with tocolytics, because of the known
danger of pulmonary edema. In our opinion,
severe preeclampsia does not, as a rule, permit
the application of a lung maturation treatment,
because, with this clinical picture, it is usually of
primary importance to terminate the pregnancy
as quickly as possible.
RDS prophylaxis in diabetics is controversial, al-
though it has been considered justifiable [14].
Under the steroid therapy, we observed attacks
of fever above 38.5 degrees in 7 of 27 diabetic
women and, in 5 of 27, serious alterations in
the glucose level and insulin requirement. Despite
intensive medical treatment, one of 27 patients
died of a severe pulmonary Klebsiella infection
with artificial respiration.
Premature rupture of the amnion is thought to
lead, via fetal stress, to an increased endogenous
glucocorticoid production which in its turn redu-
ces the incidence of RDS. In any case, BERKOWITZ
[2] was able to demonstrate a decrease of RDS
cases as well as an increase in the L/S ratio after
premature rupture of the amnion if this happened
earlier than 16 or 24 hours in pregnancies before
the 32nd week of pregnancy. We proceed at our
clinic according to the following scheme (table I).
Intrauterine infections do not as a rule permit a
continuation of the endangered pregnancy.
TAESCH et al [13] point out the connection between
glucocorticoid treatment and a doubling of the
maternal and neonatal infection risk, particularly
if the premature rupture of the amnion happened
a long time before.
There are also reports to the contrary [4]. We
consider it possible to perform antibiotic therapy
in the mother after premature rupture of the am-
nion but nevertheless view this measure as extre-
mely problematic with regard to its effect on the
fetus.
On the whole, the substances have become gen-
erally accepted in clinical practice for the perform-
ance of a prenatal lung maturation treatment.
These are betamethasone and dexamethasone. Al-
ternative therapies will be discussed later at this
congress. The application schemes are shown in
table II.
The usefulness of an RDS prophylaxis with gluco-
corticoids has been confirmed by several prospec-
tive studies in the past. All investigations demon-
strate a marked reduction of the RDS frequency
(table III). An RDS prophylaxis should be
weighed against the possible risks as a matter of
principle in cases where a premature birth is to
be expected. In this connection, the indication
should be established all the earlier, the more
immature the expected premature infant will be.
Table I. Management of premature rupture of membranes.



















— delivery after 24—48 hrs
— corticoids (?)
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4 χ 4.0 mg i. m. 0/12/24/36 hrs
2 χ 12.0mgi.m. 0/24 hrs
4 χ 5.0 mg i. m. 0/12/24/36 hrs
(Ob. Gyn. Dept. Steglitz)
[8]
[3]
Detailed results are available from the Collabora-
tive Group on Antenatal Steroid Therapy [3]. Ac-
cordingly, a particularly marked advantage is rec-
ognizable for singleton pregnancies with a reduc-
tion of RDS incidence from 18 to 12.6%. Female
fetuses profit in a very particular way (table IV).
The often discussed negative effects on neonatal
development, particularly of the brain, have not
been confirmed [1, 11, 16].
Our own results are presented on the basis of
637 non-randomized cases from the years 1980 to
1985. In about one third of our cases, an RDS
prophylaxis was carried out in underweight chil-
Table III. RDS incidence after glucocorticoid application
in pregnancy; results from the literature [12].
Prospective studies RDS incidence
LIGGINS and HOWIE, 1972
BLOCK et al, 1977
MORRISON et al, 1978
BALLARD et al, 1979
TAEUSCH et al, 1979
PAPAGEORGIOU et al, 1979
DORAN et al, 1980
























Table IV. Results of antenatal glucocorticoid therapy
(dexamethasone), obtained by the Collaborative Group
on Antenatal Steroid Therapy [3].
Incidence of RDS lower
Incidence of RDS lower
in singletons
Higher benefit of treat-
ment in female newborns
12.6% vs. 18.0%
10.1% vs. 16.0%
4.8% vs. 18.8%: 9
14.9% vs. 14.1%: S
Neuromotoric development not impaired
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dren. In the group of untreated cases, we have
fewer neonatal RDS than in the treated collective,
which is already an indication of the different risk
grouping. One hundred ninety-four of 637 living
premature infants below 2500 g birth weight re-
ceived prophylactic treatment with betametha-
sone. Forty-seventy infants with RDS occurred in
this group. In contrast, we had only 30 infants
with RDS in 443 untreated pregnancies. This is
of course due to the incomparability of the collect-
ives.
The dependence of the therapeutic result on the
sex of the newborn is also substantiated by our
cases. The neonatal course of 50 boys was com-
pared with that of 45 girls weighting ^ 2000 g
(appropriate for gestational age babies). The RDS
incidence was significantly different in the two
groups after a betamethasone prophylaxis. It was
1/25 (4%) in the girls compared to 13/31 (42%)
in the boys group (table V).
Table V. Incidence of RDS according to the sex of the
newborn. Significantly lower incidence of RDS in female




















If we check in our data the effectiveness of a
betamethasone treatment, we see that, both in the
collective of the Heidelberg University Clinic [6]
and in our own cases, a marked reduction of the
RDS incidence was only detectable after betame-
thasone therapy as of the 32nd week of pregnancy
(table VI). Up to that time, nearly every second
child develops a respiratory distress syndrome de-
spite RDS prophylaxis, the severe forms of stages
III and IV predominating, but after corticoid
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Table VI. Incidence of neonatal RDS after betamethasone treatment in pregnancy in correlation to gestational age
at birth; comparison of two university departments.
Weeks of
pregnancy















































































Table VII. Distribution of RDS grade I-IV with and
without antenatal corticoid therapy. Higher incidence
of RDS specific mortality and more severe grades of


































treatment a change towards less severe stages (I
and II) can be shown and the mortality due to
RDS (III and IV) is remarkably lower (table VII).
Conclusions: We recommend RDS prophylaxis for
all premature contractions between the 32nd and
34th week of pregnancy inclusively. In addition,
it should be given in cases of confirmed lung
immaturity. Special restrictions are necessary in
cases of preeclampsia, eclampsia, diabetes and
confirmed maternal infections. In the group of
diabetics or preeclamptic patients, an RDS pro-
phylaxis should only be given, if at all, when it can
be performed under intensive medical conditions.
Summary
Main indications for antenatal administration glucocor-
ticoid to pregnant women are premature contractions,
hemorrhage during pregnancy, conditions of fetal dis-
tress and maternal diseases. There are some absolute
or relative contraindications as well: severe forms of
preeclampsia, diabetes mellitus, premature rupture of
membranes, maternal and/intrauterine infections.
In a retrospective evaluation of the data obtained at our
institution of 637 nonrandomized cases from the years
1980 — 1985, we could demonstrate the dependence of
the therapeutic results on the sex of the newborn. The
RDS incidence is significantly different after betametha-
sone prophylaxis. It was 1/25 (4%) in girls compared to
13/31 (42%) in boys.
A marked reduction of the RDS incidence is only detect-
able after betamethasone therapy from the 32nd to the
34th week of gestation. Thus we recommend RDS pro-
phylaxis for all patients with premature contraction,
mainly between the 32nd and 34th week of pregnancy.
In addition, it should be given in cases of confirmed
lung immaturity. Special restrictions are necessary in
cases of preeclampsia, eclampsia, diabetes and con-
firmed maternal infections. In the group of diabetes or
preeclampsia patients an RDS prophylaxis should only
be given, if at all, when it can be performed under
intensive care conditions.
Keywords: Antenatal glucocorticoid treatment, prematurity, prevention of neonatal respiratory distress syndrome.
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Zusammenfassung
Klinische Aspekte der antepartalen Glukokortikoidbe-
handlung zur Prävention des Atemnotsyndroms des Neu-
geborenen
Die hauptsächlichen Indikationen zur antepartalen Glu-
kokortikoidgabe an schwangere Frauen sind vorzeitige
Wehen, Blutungen in der Spätschwangerschaft, fetal di-
stress and mütterliche Erkrankungen. Andererseits gibt
es einige absolute bzw. relative Kontraindikationen:
Schwere Formen der Präeklampsie, insulinpflichtiger
Diabetes mellitus, vorzeitiger Blasensprung sowie müt-
terliche bzw. fetale uterine Infektionen.
In einer retrospektiven Auswertung der Daten, die an
der Frauenklinik des Klinikums Berlin-Steglitz an 637
nicht randomisierten Fällen in den Jahren 1980 bis 1985
erhalten wurden, konnten wir die Abhängigkeit des the-
rapeutischen Effektes der Kortikoidbehandlung vom
Geschlecht des Neugeborenen nachweisen. Die Inzidenz
des Atemnotsyndroms ist signifikant unterschiedlich
nach Betamethasonprophylaxe: Sie betrug 1/25 (4%) bei
Mädchen, verglichen zu 13/31 (42%) bei Knaben.
Eine deutliche Reduktion der Inzidenz des Atemnotsyn-
droms ließ sich nur nach Betamethasontherapie zwi-
schen der 32. bis zur 34. SSW nachweisen. Deshalb
empfehlen wir die RDS-Prophylaxe für alle Patientinnen
mit vorzeitiger Wehentätigkeit insbesondere zwischen
der 32. und 34. SSW. Außerdem sollten Glukokortikoide
gegeben werden bei allen Fällen mit durch Fruchtwasser-
analyse gesicherter zu erwartender Lungenunreife. Spe-
zielle Vorsichtsmaßnahmen sind notwendig in Fällen
von Präemklampsie, Eklampsie, Diabetes und gesicher-
ter mütterlicher Infektion. In der Gruppe der Diabetike-
rinnen oder Präeklampsiepatientinnen darf eine RDS-
Prophylaxe nur dann durchgeführt werden, wenn dies
unter intensivmedizinischen Bedingungen geschehen
kann.
Schlüsselwörter: Antepartale Glukokortikoidbehandlung, fetale Unreife, Prävention des Atemnotsyndroms bei
Neugeborenen.
Resume
Aspects cliniques du traitement antenatal par glucocorti-
coides pour la prevention du SDR neonatal
Les indications principales du traitement antenatal par
glucocortico'ides chez la femme enceinte sont les contrac-
tions prematurees, les hemorragies de la grossesse, les
situations de souffrances foetales et les maladies mater-
nelles. II existe certaines contre-indications absolues ou
relatives: preeclampsie severe, diabete sucre, rupture pre-
maturee des membranes, infections maternelles et intrau-
terines.
Dans revaluation retrospective des donnees obtenues
dans notre institution concernant 637 cas non randomi-
ses de 1980 ä 1985, nous avons pu demontrer que les
resultats de la therapeutique dependent du sexe du
nouveau-ne. L'incidence du SDR est significativement
differente apres prophylaxie par betamethazone. Elle est
de 1/25 (4%) chez les fllles et en comparaison de 13/31
(42%) chez les gargons.
On ne detecte une diminution nette de l'incidence du
SDR apres traitement par betamethazone qu'entre 32 et
34 semaines. Aussi, nous recommendons une prophy-
laxie du SDR pour toutes les patientes ayant des contrac-
tions prematurement, particulierement entre 32 et 34
semaines. En outre, cette prophylaxie devrait etre propo-
see en cas d'immaturite pulmonaire confirmee. Des limi-
tations speciales sont necessaires en cas de preeclampsie,
d'eclampsie, de diabete et d'infection maternelle
confirmee. Dans le groupe des patiente preeclampsiques
ou diabetiques on ne devrait proposer une prophylaxie
du SDR que si alle peut etre realisee, environnee de
soins intensifs.
Mots-cles: Prematurite, prevention du syndrome de detresse respiratoire neonatale, traitement antenatal par
glucocortico'ides.
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